Cargando…
A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.
A fluorinated 2-nitroimidazole radiosensitizer KU-2285 was given before intraoperative radiotherapy (IORT) to 30 patients with unresectable, unresected or macroscopic residual tumours. Twenty-three patients had pancreatic cancer and five had osteosarcoma. The IORT dose was 30 Gy for unresectable pan...
Autores principales: | Shibamoto, Y., Ohshio, G., Hosotani, R., Nishimura, Y., Manabe, T., Imamura, M., Abe, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228186/ https://www.ncbi.nlm.nih.gov/pubmed/9400944 |
Ejemplares similares
-
Comparison of in vivo Efficacy of Hypoxic Cytotoxin Tirapazamine and Hypoxic Cell Radiosensitizer KU‐2285 in Combination with Single and Fractionated Irradiation
por: Shibata, Toru, et al.
Publicado: (1996) -
Assessment of the proliferative activity and radiosensitivity of human tumours using the cytokinesis-block micronucleus assay.
por: Shibamoto, Y., et al.
Publicado: (1994) -
A New, Potent 2‐Nitroimidazole Nucleoside Hypoxic Cell Radiosensitizer, RP170
por: Sasai, Keisuke, et al.
Publicado: (1989) -
2285 Patient navigation training: Community-engaged workforce development
por: Ahuja, Nirmal, et al.
Publicado: (2018) -
Radiosensitizers of Hypoxic Cells
por: Nias, A. H. W.
Publicado: (1980)